. Author manuscript; available in PMC: 2009 Jul 1.

Published in final edited form as: Vascul Pharmacol. 2008 Apr 3;49(1):6–13. doi: 10.1016/j.vph.2008.03.005

Table 1.

Maximum contraction and estimated EC₅₀ values for ET-1 (10 pM – 100 nM) - induced contraction in rat thoracic aorta and vena cava under control conditions, ET_A receptor blockade, ET_B receptor desensitization and ET_A blockade plus ET_B receptor desensitization.

	Aorta		Vena cava

Treatment	Max contraction [% PE (10 μM)]	EC₅₀ (nM)	Max contraction [% NE (10 μM)]	EC50 (nM)
Vehicle	139±20	6.95±2.13 ^†	561±56	10.58±4.84 ^†
Atrasentan (10 nM)	122±22	19.90±1.12^* ^†	470±33	8.15±0.60 ^†
S6c (100 nM)	141±7	7.74±1.60^*	403±75^*	6.68±1.90
Atrasentan (10 nM) + S6c (100 nM)	102±8^* ^†	32.15±13.25^* ^†	319±63^*	22.45±4.70^* ^†

Data are represented as mean ± S.E.M. Atrasentan, ETA receptor antagonist; NE, norepinephrine; PE, phenylephrine; S6c, (sarafotoxin 6c) ETB receptor agonist.

represents a statistically significant difference from control (p<0.05)

^†

represents a statistically significant difference from S6c (p<0.05).